These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17371824)

  • 1. Evolution of resistant M414T mutants among hepatitis C virus replicon cells treated with polymerase inhibitor A-782759.
    Lu L; Mo H; Pilot-Matias TJ; Molla A
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1889-96. PubMed ID: 17371824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.
    Mo H; Lu L; Pilot-Matias T; Pithawalla R; Mondal R; Masse S; Dekhtyar T; Ng T; Koev G; Stoll V; Stewart KD; Pratt J; Donner P; Rockway T; Maring C; Molla A
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4305-14. PubMed ID: 16189112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
    Shi ST; Herlihy KJ; Graham JP; Fuhrman SA; Doan C; Parge H; Hickey M; Gao J; Yu X; Chau F; Gonzalez J; Li H; Lewis C; Patick AK; Duggal R
    Antimicrob Agents Chemother; 2008 Feb; 52(2):675-83. PubMed ID: 18070954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
    Ali S; Leveque V; Le Pogam S; Ma H; Philipp F; Inocencio N; Smith M; Alker A; Kang H; Najera I; Klumpp K; Symons J; Cammack N; Jiang WR
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4356-69. PubMed ID: 18838588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor.
    Nguyen TT; Gates AT; Gutshall LL; Johnston VK; Gu B; Duffy KJ; Sarisky RT
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3525-30. PubMed ID: 14576112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.
    Howe AY; Cheng H; Johann S; Mullen S; Chunduru SK; Young DC; Bard J; Chopra R; Krishnamurthy G; Mansour T; O'Connell J
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3327-38. PubMed ID: 18559648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cell-based assay for RNA synthesis by the HCV polymerase reveals new insights on mechanism of polymerase inhibitors and modulation by NS5A.
    Ranjith-Kumar CT; Wen Y; Baxter N; Bhardwaj K; Cheng Kao C
    PLoS One; 2011; 6(7):e22575. PubMed ID: 21799903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
    Chen CM; He Y; Lu L; Lim HB; Tripathi RL; Middleton T; Hernandez LE; Beno DW; Long MA; Kati WM; Bosse TD; Larson DP; Wagner R; Lanford RE; Kohlbrenner WE; Kempf DJ; Pilot-Matias TJ; Molla A
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4290-6. PubMed ID: 17908950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
    Herlihy KJ; Graham JP; Kumpf R; Patick AK; Duggal R; Shi ST
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3523-31. PubMed ID: 18694956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.
    Chase R; Skelton A; Xia E; Curry S; Liu S; McMonagle P; Huang HC; Tong X
    Antiviral Res; 2009 Nov; 84(2):178-84. PubMed ID: 19747948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
    Lam AM; Murakami E; Espiritu C; Steuer HM; Niu C; Keilman M; Bao H; Zennou V; Bourne N; Julander JG; Morrey JD; Smee DF; Frick DN; Heck JA; Wang P; Nagarathnam D; Ross BS; Sofia MJ; Otto MJ; Furman PA
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3187-96. PubMed ID: 20516278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.
    Kati W; Koev G; Irvin M; Beyer J; Liu Y; Krishnan P; Reisch T; Mondal R; Wagner R; Molla A; Maring C; Collins C
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1505-11. PubMed ID: 25534735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allele-specific real-time PCR system for detection of subpopulations of genotype 1a and 1b hepatitis C NS5B Y448H mutant viruses in clinical samples.
    Bae AS; Ku KS; Miller MD; Mo H; Svarovskaia ES
    J Clin Microbiol; 2011 Sep; 49(9):3168-74. PubMed ID: 21715590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.
    Wang C; Huang H; Valera L; Sun JH; O'Boyle DR; Nower PT; Jia L; Qiu D; Huang X; Altaf A; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1350-8. PubMed ID: 22214777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypic and phenotypic analyses of hepatitis C virus from patients treated with JTK-853 in a three-day monotherapy.
    Ogura N; Toyonaga Y; Ando I; Hirahara K; Shibata T; Turcanu G; Pai S; Yee K; Gerhardt B; Rodriguez-Torres M; Noguchi T
    Antimicrob Agents Chemother; 2013 Jan; 57(1):436-44. PubMed ID: 23129048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations.
    Middleton T; He Y; Pilot-Matias T; Tripathi R; Lim BH; Roth A; Chen CM; Koev G; Ng TI; Krishnan P; Pithawalla R; Mondal R; Dekhtyar T; Lu L; Mo H; Kati WM; Molla A
    J Virol Methods; 2007 Nov; 145(2):137-45. PubMed ID: 17604129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus.
    Le Pogam S; Kang H; Harris SF; Leveque V; Giannetti AM; Ali S; Jiang WR; Rajyaguru S; Tavares G; Oshiro C; Hendricks T; Klumpp K; Symons J; Browner MF; Cammack N; Nájera I
    J Virol; 2006 Jun; 80(12):6146-54. PubMed ID: 16731953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
    Shi ST; Herlihy KJ; Graham JP; Nonomiya J; Rahavendran SV; Skor H; Irvine R; Binford S; Tatlock J; Li H; Gonzalez J; Linton A; Patick AK; Lewis C
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2544-52. PubMed ID: 19307358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical characterization of JTK-853, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
    Ando I; Adachi T; Ogura N; Toyonaga Y; Sugimoto K; Abe H; Kamada M; Noguchi T
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4250-6. PubMed ID: 22615294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Replication of the subgenomic hepatitis C virus replicon in the presence of the NS3 protease inhibitors: a stochastic model].
    Ivanisenko NV; Mishchenko EL; Akberdin IR; Demenkov PS; Likhoshvai VA; Kozlov KN; Todorov DI; Samsonova MG; Samsonov AM; Kolchanov NA; Ivanisenko VA
    Biofizika; 2013; 58(5):758-74. PubMed ID: 25481944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.